Please ensure Javascript is enabled for purposes of website accessibility

Why AnaptysBio Stock Is Popping Today

By Prosper Junior Bakiny - Updated Mar 16, 2021 at 1:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This analyst is excited about the company's prospects.

What happened

Shares of clinical-stage biotech AnaptysBio (ANAB -0.76%) were rising sharply on Tuesday following bullish commentary from a Wall Street analyst. The company's stock was up by 5.6% as of 12:58 p.m. EDT, after rising by as much as 12% earlier in the day.

So what

Truist analyst Joon Lee upgraded AnaptysBio stock to buy from hold. Lee also gave the company's shares a new price target of $34, up from $27. As of this writing, shares are trading for $20.97. Clearly, Lee sees significant upside for the biotech. But what is the analyst's reasoning behind this vote of confidence?

First, it's important to remember that AnaptysBio's stock recently dropped by more than 30% after one of its leading pipeline candidates, imsidolimab, failed to meet its primary endpoint in a clinical trial for the treatment of moderate to severe palmoplantar pustulosis. 

Doctor giving a thumbs up.

Image source: Getty Images.

After this sell-off, Lee believes that AnaptysBio is a buy at current levels, especially given that, in his view, the company has several catalysts coming in the next 12 to 18 months that could push its stock price higher. The analyst thinks that imsidolimab may deliver positive results in a phase 2 clinical trial for EGFRi-mediated skin toxicity. Topline data from this study is expected by the end of 2021.

Lastly, with AnaptysBio gearing up to start a phase 3 clinical trial for imsidolimab as a treatment for generalized pustular psoriasis, Lee sees the market in this indication as being potentially much larger than even he currently models.

Now what

Analyst recommendations are always worth considering, but in my view, AnaptysBio seems like a risky bet at the moment. Sure, the company's upside, if its current programs pan out, seems enticing. But on the flip side, negative results from clinical trials or regulatory roadblocks would send the healthcare stock crashing.

This is especially the case since AnaptysBio doesn't have any products on the market at the moment. In short, I think it is worth keeping an eye on this company, but only investors comfortable with above-average risk and volatility should consider initiating a position. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AnaptysBio Stock Quote
$20.97 (-0.76%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.